Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT00722072
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 396
- Registration Number
- NCT00688194
- Locations
- 🇮🇹
Federico II University Medical School, Naples, Italy
Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2010-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00660803
- Locations
- 🇧🇷
Research Site, Sao Paulo, SP, Brazil
Second Line Breast Cancer Trial
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 588
- Registration Number
- NCT00635713
Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 116
- Registration Number
- NCT00629616
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷Hopital Dupuytren, Limoges Cedex, France
🇫🇷Centre Eugene Marquis, Rennes, France
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 26
- Registration Number
- NCT00617188
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Lyudmila Bazhenova, M.D.
- Target Recruit Count
- 7
- Registration Number
- NCT00592007
- Locations
- 🇺🇸
Moores UCSD Cancer Center, La Jolla, California, United States
Efficacy and Safety of 500mg of Fulvestrant
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00585507
- Locations
- 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Mara Chambers
- Target Recruit Count
- 33
- Registration Number
- NCT00570921
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 27
- Registration Number
- NCT00570258
- Locations
- 🇺🇸
Hackensack University, Hackensack, New Jersey, United States
🇺🇸St. Luke's Cancer Institute, Kansas City, Missouri, United States
🇺🇸NEA Clinic, Jonesboro, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.